Mathilde Bonnet

Title: Mathilde Bonnet: Innovator in Cancer Therapy

Introduction

Mathilde Bonnet is a notable inventor based in Vic le Comte, France. She has made significant contributions to the field of cancer therapy, particularly in predicting resistance to anti-PD1 therapy in colorectal cancer patients. Her innovative approach has the potential to improve treatment outcomes for individuals suffering from this challenging disease.

Latest Patents

Mathilde Bonnet holds a patent titled "PKS-island positive as marker of negative response to anti-PD1 therapy in colorectal cancer." This patent outlines a method for predicting resistance to anti-PD1 therapy by determining the presence of a bacterial pks island from a biological sample, such as feces or a colonic biopsy. The method not only predicts resistance but also provides insights into treating cancer by assessing the presence of this bacterial marker.

Career Highlights

Throughout her career, Mathilde has worked with prominent organizations, including Sanofi and Université Clermont Auvergne. Her work in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research in cancer treatment.

Collaborations

Mathilde has collaborated with esteemed colleagues such as Elisabeth Billard and Bruno Dumas. These partnerships have enriched her research and expanded the impact of her innovations in cancer therapy.

Conclusion

Mathilde Bonnet's contributions to cancer therapy through her innovative patent and collaborations highlight her role as a leading inventor in the medical field. Her work continues to pave the way for advancements in cancer treatment and patient care.